France· FR:62251899
OCREVUS 920 mg, solution injectable
A medicinal product containing ocrélizumab, registered in France by ROCHE REGISTRATION (ALLEMAGNE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- OCRÉLIZUMAB
- Manufacturer
- ROCHE REGISTRATION (ALLEMAGNE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009551018951 flacon en verre de 23 mL
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ocrélizumab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandOcrevus 920 mg solution for injectionRoche Registration GmbH
- NetherlandsOcrevus 920 mg oplossing voor injectieRoche Registration GmbH
- FinlandOcrevusRoche Registration GmbH
- CzechiaOCREVUSRoche Registration GmbH, Grenzach-Wyhlen
- United KingdomOcrevus 300mg/10ml concentrate for solution for infusion vialsRoche Products Ltd
- BelgiumOcrevus 300 mgRoche Registration
- SwitzerlandOcrevus subkutan 920 mg/23 ml, InjektionslösungRoche Pharma (Schweiz) AG
- SpainOCREVUS 300 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ocrevus
- Liechtenstein · Ocrevus
- Norway · Ocrevus
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/62477b4e-bfec-494d-b267-2f632a0f90ca GET /v1/drugs/62477b4e-bfec-494d-b267-2f632a0f90ca?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "62251899",
"date_amm": "2024-06-20",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/17/1231",
"substance": "OCRÉLIZUMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution injectable",
"voies_administration": "sous-cutanée",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about ocrélizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.